Navigation Links
Study shows no evidence of a mortality benefit to PSA screening
Date:1/6/2012

Men enrolled in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial had no evidence of a mortality benefit compared to a control group of men undergoing usual care, according to a study published online Jan. 6 in the Journal of the National Cancer Institute.

The Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) Trial is a multi-center, two-arm trial, which began enrollment in November 1993 with follow-up through December 2009, and was designed to evaluate the effect of screening on these specific cancers. The enrollees were aged 55-74 and had no previous personal history of these cancers. Men in the intervention arm underwent annual PSA testing for six years and annual digital rectal examination for four years, while those in the control arm received their usual medical care, which for some men included screening. A previous report of PLCO results through ten years was criticized for being too short of a follow-up period.

To determine longer-range outcomes among the men enrolled in PLCO, Gerald L. Andriole, M.D., of Washington University School of Medicine in St. Louis, and colleagues, examined outcomes of the men through 13 years. The researchers found a statistically significant 12% relative increase in the incidence rate of prostate cancer, and a non-statistically significant decrease in the incidence of high-grade prostate cancer in the intervention arm compared to the control arm, but no difference in mortality between the two arms. In addition, there was no apparent differential effect of screening by age category, pre-trial PSA testing, or co-morbidity.

The authors write, "Improvements in prostate cancer treatment are probably at least in part responsible for declining prostate cancer mortality rates. Even if life is only prolonged by therapy, the opportunities for competing causes of death increase, especially among older men."

The authors also point out that of the 425
'/>"/>

Contact: Zachary Rathner
Zachary.Rathner@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study Offers Clues to Why Some Dont Benefit From Asthma Drugs
2. Mice Exposed to Smoke Helped by Blood Pressure Drug: Study
3. Global Study Finds Drug Abuse Highest in Richer Nations
4. Diabetes Care Thwarted by Unstable Health Insurance: Study
5. Moderate red wine drinking may help cut womens breast cancer risk, Cedars-Sinai study shows
6. Mental Decline Can Start at 45, Study Finds
7. Study finds statin costs 400 percent higher in US compared to UK
8. Drug Eases Gout Flare-ups in Some Patients: Study
9. Study Reveals Whos More Prone to Be a Mean Drunk
10. Kaiser Permanente study finds continuous health coverage essential for patients managing diabetes
11. Safety-First Playgrounds Linked to Bored, Inactive Kids: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... November 27, 2014 In a ... allot to sleep has lessened, and due to ... the quality of sleep has eroded. According to ... on the job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This ... index by an incalculable amount, leading not only ...
(Date:11/27/2014)... York (PRWEB) November 27, 2014 ... have been filed in a consolidated litigation now ... reports. , Documents recently updated in the ... included in the state proceeding, all of which ... disorder and other psychiatric conditions. Many of the ...
(Date:11/27/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals ... eat a gluten-free diet, an expert says. Many ... potatoes and cranberry sauce -- are gluten-free, but "when ... may need to be considered," Dr. Anca Safta, director ... Wake Forest Baptist Medical Center in North Carolina, said ...
(Date:11/27/2014)... Now that Thanksgiving is finally here and ... Emassagechair.com has announced its eagerly awaited, once yearly ... Negotiating on behalf of their customers, and drawing on ... has generated significant buzz in the industry with the ... , Shoppers are excited for significant savings available on ...
(Date:11/27/2014)... DC (PRWEB) November 27, 2014 “Wekho” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review ... locations instead of people. , An interesting new way to ... iOS and Android devices. It’s called Wekho and it’s ...
Breaking Medicine News(10 mins):Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2
... ... of rural Hispanic families found that untreated tooth decay in mothers almost doubled the odds ... of mothers and their children, the authors say. , ... (Vocus) June 15, 2010 -- A UCSF study examining the oral ...
... a greater likelihood of poorer outcomes, many patients newly-diagnosed ... research indicates that among the factors associated with this ... patient-physician communication and older age, with black patients more ... in the June 16 issue of JAMA . ...
... patients and can reduce costs, study finds , TUESDAY, June ... as well as high doses of injected steroids for patients ... , Yet, some 90 percent of these COPD patients are ... guidelines, claims the study appearing in the June 16 ...
... The ... Tao Text for the 21st Century and Presents the Essence and Secrets of Ancient Teachings ... and More, , ... 2010 -- In the newly released sixth book of his best-selling Soul Power Series, Tao I: ...
... ... specializing in Emergency Department and Hospitalist Medicine Management companies, partners with Lock Haven ... Pennsylvania., , ... Ft. Lauderdale, Florida (Vocus) June 15, 2010 -- Hospital Physician Partners ...
... pandemic influenza vaccine and then exposed to high levels of ... get sick or die, report scientists funded by the National ... National Institutes of Health. The new vaccine works against the ... H1N1 influenza share features that allow vaccine-generated antibodies to recognize ...
Cached Medicine News:Health News:If Mother Has Tooth Decay, Odds Increase That Child Does Too 2Health News:If Mother Has Tooth Decay, Odds Increase That Child Does Too 3Health News:Study examines reasons patients with early stage lung cancer do not have surgery 2Health News:Study examines reasons patients with early stage lung cancer do not have surgery 3Health News:IV Steroids May Be Overkill in COPD Patients 2Health News:IV Steroids May Be Overkill in COPD Patients 3Health News:TAO l: The Way of All Life, by Zhi Gang Sha Reaches #6 on New York Times Bestseller List 2Health News:TAO l: The Way of All Life, by Zhi Gang Sha Reaches #6 on New York Times Bestseller List 3Health News:Hospital Physician Partners and Lock Haven Hospital Announce New Emergency Department Partnership 2Health News:Hospital Physician Partners and Lock Haven Hospital Announce New Emergency Department Partnership 3Health News:NIH-funded scientists find 2009 H1N1 pandemic influenza vaccine protects mice from 1918 flu virus 2
(Date:11/26/2014)... Investor-Edge has initiated coverage on the ... Pharma PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... JNJ ), and Theravance Inc. (NASDAQ: THRX ). ... http://investor-edge.com/register . On Tuesday, November 25, 2014, ... Jones Industrial Average edged 0.02% lower, to finish the day ...
(Date:11/26/2014)... SHANGHAI , Nov. 26, 2014  CARsgen, a ... (CAR-T) cell immunotherapy to treat a variety of cancers, ... led by BVCF, a China -based ... an immunotherapy company focused on the development of new ... collaboration with Shanghai Cancer Institute and Shanghai Renji Hospital, ...
(Date:11/26/2014)... Nov. 25, 2014  At the American Dental Association,s ... this October, KaVo Kerr Group was honored to be ... attendees the opportunity to see and test the Best ... leaders deliver lectures on the latest developments in dental ... the new DEXIS CariVu Caries Detection Device and Kerr ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... 2011 ViroPharma Incorporated (Nasdaq: VPHM ) today ... ViroPharma, will present at the Citi 2011 Global Healthcare Conference ... conference is being held at the Hilton New York Hotel ... and chief financial officer, of ViroPharma, will present at the ...
... Feb. 28, 2011 Rock Creek Pharmaceuticals, a wholly ... CIGX ) has been notified by the Roskamp Institute ... review board (IRB) approval to conduct a three-month, multi-site ...  The study (referred to as the "Flint Study"), will ...
Cached Medicine Technology:ViroPharma to Participate in Two March Healthcare Conferences 2Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound 2Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound 3Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound 4
Toothed Pituitary IVD Rongeurs, 8 length 200 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
Medicine Products: